Insight Molecular Diagnostics (IMDX) EBIAT (2020 - 2025)
Historic EBIAT for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$10.9 million.
- Insight Molecular Diagnostics' EBIAT rose 1955.83% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.8 million, marking a year-over-year decrease of 4087.24%. This contributed to the annual value of -$60.7 million for FY2024, which is 11836.15% down from last year.
- As of Q3 2025, Insight Molecular Diagnostics' EBIAT stood at -$10.9 million, which was up 1955.83% from -$9.7 million recorded in Q2 2025.
- Over the past 5 years, Insight Molecular Diagnostics' EBIAT peaked at $6.0 million during Q1 2023, and registered a low of -$45.0 million during Q4 2022.
- In the last 5 years, Insight Molecular Diagnostics' EBIAT had a median value of -$9.7 million in 2025 and averaged -$13.1 million.
- Its EBIAT has fluctuated over the past 5 years, first plummeted by 46879.06% in 2021, then skyrocketed by 15790.5% in 2023.
- Over the past 5 years, Insight Molecular Diagnostics' EBIAT (Quarter) stood at -$35.9 million in 2021, then decreased by 25.34% to -$45.0 million in 2022, then soared by 64.44% to -$16.0 million in 2023, then tumbled by 109.55% to -$33.5 million in 2024, then skyrocketed by 67.61% to -$10.9 million in 2025.
- Its EBIAT was -$10.9 million in Q3 2025, compared to -$9.7 million in Q2 2025 and -$6.7 million in Q1 2025.